Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ Email and Phone Number

Peer Reviewer in AI applied to Genetics @ Springer Nature Group
New York, NY, US
Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ's Location
New York City Metropolitan Area, United States
Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ's Contact Details

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ work email

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ personal email

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ phone numbers

About Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ

โ€œNot failingโ€ฆ is a failure. We should all ask ourselves: Am I under-failing?โ€ โ€”Amanda Askell, Anthropicโ€™s Philosopher in ResidenceI love this quote. It reminds me of one from the legend, Michael Jordan: "You miss 100% of the shots you don't take." In my life, I may have over-failed. I failed Wall Street. I failed my friends and colleagues. I lost many of them, literally overnight. But my real friends, family, and professional colleaguesโ€”those who stood by me through thick and thinโ€”will vouch for this: I will never fail them. My love and loyalty are stronger than anyone's on this earth.Throughout my career, I have consistently demonstrated a commitment to loyalty, honesty, and intellectual curiosity, qualities that those who have worked closely with me can attest to. My contributions have significantly benefited the companies and individuals I have collaborated with, creating wealth and fostering success. I take pride in my ability to mentor and help others, particularly those in need, and find great satisfaction knowing that many individuals credit their current roles to the opportunities I've helped create.Throughout my life's trials and tribulations, I have been fortunate to be surrounded by a supportive network of family, friends, and professional colleagues, many of whom are industry leaders. These individuals, despite having full knowledge of my life challenges, have generously provided references that attest to my character and competence.The experiences I've had and the network I've built have shaped me into a well-rounded professional. I'm grateful for all of itโ€”the good, the bad, the easy, and the challenging. I believe that all these experiences have prepared me for future opportunities, and I eagerly look forward to what lies ahead.Instead of just speaking about myself, I'd like to share a couple quotes from former bosses and business partners who've known me throughout my career.โ€œSergei is one of the most talented, determined, and bright individuals I have ever known. Heโ€™s been dedicated to doing research in the fields of finance, economics, mathematics and artificial intelligence. Sergei has a passion for research and a real zeal for learning."โ€œ[Sergei] offered me the software at no cost with hopes that it might help in my care of Covid patients. I was struck by the kindness of his offerโ€ฆ He is consistently honest, and a fair-minded in negotiations. He is kind and respectful, with a silly childlike sense of humor.โ€ Trust me with your team, and you won't regret your decision.

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ's Current Company Details
Springer Nature Group

Springer Nature Group

View
Peer Reviewer in AI applied to Genetics
New York, NY, US
Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ Work Experience Details
  • Springer Nature Group
    Peer Reviewer In Ai Applied To Genetics
    Springer Nature Group
    New York, Ny, Us
  • Springer Nature Group
    Peer Reviewer In Ai Applied To Genetics
    Springer Nature Group Dec 2021 - Present
    I'm proud that my job as an academic peer reviewer in the field of artificial intelligence (AI) applied to genetics plays a crucial role in ensuring the quality, validity, and reliability of scientific research. My primary responsibilities include: evaluating the research, assessing its novelty and significance, identifying flaws and errors, providing constructive feedback, ensuring ethical standards, and communicating with editors. I take pride in maintaining the high standards of academic research and ensuring that published studies contribute meaningful and valid scientific findings.As a Peer Reviewer at Springer for The European Journal of Human Genetics, I contribute to a premier publication of the European Society of Human Genetics. The journal is dedicated to publishing high-quality, original research papers, short reports, and reviews in the rapidly evolving field of human genetics and genomics. My specific role involves applying my expertise in artificial intelligence to the genetics domain, ensuring the validity and quality of research presented in this niche. The journal encompasses molecular, clinical, and cytogenetic studies, acting as a crucial interface between advanced biomedical research and clinical practitioners. My work further supports the journal's commitment to bridging the considerable diversity of facilities, resources, and perspectives within the global genetics community.
  • International Federation Of Clinical Chemistry And Laboratory Medicine (Ifcc)
    Member Of Artificial Intelligence And Genomic Diagnostics International Working Group (Wg-Aigd)
    International Federation Of Clinical Chemistry And Laboratory Medicine (Ifcc) Jan 2021 - Present
    The WG-AIGD working group was established in response to the COVID-19 pandemic. Our aim was to explore how we, as scientists, could utilize AI and other emerging technologies in genomic diagnostics and broader clinical medicine. Some group members previously conducted the inaugural academic review of technologies emerging to combat COVID-19, resulting in the highly cited paper "Artificial Intelligence-Powered Search Tools and Resources in the Fight Against COVID-19," published on June 2, 2020. My contribution involved examining various AI tools employed to tackle COVID-19 and elucidating their specific applications. One such tool was WellAI's COVID-19 Research Tool, which enables medical researchers to find efficient, often non-trivial ways to apply their expertise towards addressing COVID-19.The group recognized the vital importance of addressing ethical issues and best practices concerning the application of AI in clinical practice. I took the lead on this project, which resulted in an academic opinion review titled "Advancing AI in Healthcare: A Comprehensive Review of Best Practices." The review concluded that while AI possesses significant potential to enhance patient care, it also introduces risks and challenges such as maintaining privacy, battling bias, and upholding transparency and ethics. The report emphasizes the importance of promoting diverse dialogue amongst data scientists, clinicians, patient advocates, ethicists, economists, and policymakers.Currently, my focus is on developing IFCC-GPT, a version of ChatGPT dedicated to medical research. The model undergoes an initial fine-tuning process using extensive digitized datasets of medical Q&As, followed by the ingestion of tens of thousands of selected medical research articles. The model merges this trained knowledge to answer researchers' and doctors' questions in a conversational manner, potentially answering questions that have never been posed before, by synthesizing the available data.
  • Wellai
    Founder And Board Member
    Wellai Sep 2021 - Present
    New York City Metropolitan Area
    ๐ŸŽฏ Spearheaded the development of an AI-assisted Digital Front Door ecosystem for clinics and hospitals.๐ŸŽฏ Led product security and ensured HIPAA compliance.๐ŸŽฏ Managed successful AWS integration for efficient app function and operation.๐ŸŽฏ Maintained and validated AI algorithm code to ensure optimal functionality.
  • Wellai
    Founder And Ceo
    Wellai Oct 2019 - Sep 2021
    New York City Metropolitan Area
    I take great pride in the achievements made by my team and myself at WellAI. Founded amidst the COVID-19 pandemic, WellAI aimed to streamline the interaction between patients and doctors. We aspired to alleviate the burden on doctors by automating their workflow, summarizing notes and patients' medical histories, and providing an AI-based platform for diagnosis and treatment.I oversaw the development of WellAIโ€™s COVID-19 application, a vital tool for medical researchers battling the virus. Furthermore, I championed the creation of a comprehensive AI-assisted Digital Front Door ecosystem for clinics and hospitals. This unique AI platform facilitates a 30-second AI-assisted scientific triage for patients. Our Digital Front Door platform encompasses services like Telehealth, Nurse Chat, Medication Refill, Lab/Test Results, Access to Medical Records, Visual Medical Summary, and Healthcare Wallet, thus significantly reducing patient wait times.In my role as CEO, I have made countless phone calls, composed hundreds of thousands of emails, and negotiated with a myriad of venture capitalists, esteemed investors, vendors, partners, and customers. The relentless efforts of my team have enabled our unique AI technology to assist thousands of patients and a host of clinicians every day.WellAI is revolutionizing primary care and optimizing hospital workflow solutions through comprehensive voice-guided scientific triage, AI-based telehealth, convenient telehealth scheduler, compliant nurse chat, automatic clinician note generation, along with an exceptionally accurate AI diagnostic tool - all within the AWS-based HIPAA-compliant platform.Harnessing insights from over 30 million medical studies, and still counting, our AI precision model boasts an accuracy rate of 83% for top-three diagnoses based on 2,400 vignettes (sets of symptoms). WellAI notably reduces a patient's onboarding time from the US national average of 23 minutes to just 7 minutes.
  • Q Group
    Committee Member
    Q Group Apr 2019 - Present
    I've served on Administration, Budget & Audit Committee.From its inception in 1966, the Q Group (The Institute for Quantitative Research in Finance) has provided a forum for investment professionals to advance the practice of global investment management by connecting investment professionals with rigorous research and ideas at the frontier of the industry.With an interest in research for applications (rather than the theoretical), the Q Group celebrates research that demonstrates a grounded logic and a disciplined scientific methodology in finance, economics and those crossing disciplines. Through its semi-annual seminars, the Q Group provides opportunities for investment professionals to learn about new research in quantitative finance from leading scholars working in the field.Internationally recognized, the Q Group seminars offer a forum where those working in the industry can engage the academic community in a spirited dialogue of cutting-edge theory and its potential value in real life applications.
  • Council Of Europe
    Lecturer In Economics And Investments At The East European School Of Political Studies
    Council Of Europe Jun 2016 - Present
    My teaching responsibilities focus on equipping the young leaders of Belarus with up-to-date knowledge of economic principles and contemporary investment models.
  • Society Of Quantitative Analysts (Sqa)
    Board Director
    Society Of Quantitative Analysts (Sqa) Jun 2009 - Sep 2021
    Greater New York City Area
    During my 12-year tenure on the SQA board, I had the privilege of collaborating with some of the most distinguished professionals in the quantitative finance industry. I was actively involved in every SQA seminar and conference, recommending innovative research, inviting respected speakers, and assisting with event logistics, from liaising with venues and speakers to designing promotional material.Three events from my tenure stand out. The first followed the infamous AXA-Rosenberg case brought by the Securities and Exchange Commission (SEC). Amid industry debates on potential SEC double standards, I proposed a panel discussion. Despite the challenge of inviting the SEC and AXA-Rosenberg's CEO to discuss an ongoing investigation and coordinating schedules for nine panelists, we managed to host a successful event with significant industry players. The conference, "Model Risk, Quants and the Law", drew approximately 300 senior finance professionals, becoming one of SQA's most successful events.I'm also immensely proud of the โ€œSustainable Investingโ€ conference, our response to the rising trend of Environmental, Social, and Governance (ESG) investing. Urging the board to scrutinize this trend, we invited experts to present varied perspectives. This conference, attended by about 100 investment professionals, brought together academics, industry experts, environmental advocates, and Nobel Laureate Robert Schiller, marking a significant milestone in my career and the field of ESG.Finally, organizing SQAโ€™s โ€˜Fuzzy Dayโ€™ Conference and a gala for its 50th anniversary embodied teamwork and in-depth research into the organization's history. After meticulously reviewing archival material and tracing former SQA presidents, we managed to assemble an extraordinary cohort of 21 past SQA leaders. This event served as a grand celebration of SQA's enduring legacy in quantitative finance.
  • Society Of Quantitative Analysts (Sqa)
    Member
    Society Of Quantitative Analysts (Sqa) Sep 2004 - Jun 2009
    New York, New York, United States
    I participated in every SQA event, actively contributing by discussing research topics and suggesting potential speakers.
  • Qqq
    Vice President, Senior Quant, Director Of Factor Research
    Qqq Feb 2013 - Oct 2019
    New York, United States
    ๐ŸŽฏ Served as lead developer for smart beta ETFs (tickers: OMFL and OMFS), with approximately $4.4 billion in assets under management (AUM).๐ŸŽฏ Collaboratively developed and co-managed GMAT alternative risk premia strategies, overseeing a portfolio of approximately $150 million.๐ŸŽฏ Achieved recognition as the employee of the year in 2017, receiving the prestigious Donald W. Spiro Award.
  • Qqq
    Portfolio Manager, Director Of Asset Allocation Research
    Qqq Oct 2009 - Feb 2013
    New York, United States
    ๐ŸŽฏ Performed as the lead developer for OppenheimerFunds' strategic allocation strategies, managing approximately $5 billion in assets under management (AUM).๐ŸŽฏ Served as lead portfolio manager for quantitative funds (tickers: OAPPX, OAPMX, OAPRX), overseeing approximately $900 million in AUM.
  • Qqq
    Senior Risk Analyst
    Qqq Apr 2004 - Oct 2009
    New York, United States
    ๐ŸŽฏ Managed risks for retail and institutional portfolios utilizing multi-asset risk models (BarraOne, Aladdin, RiXtrema) and equity risk models (Barra, Northfield, Thomson/Vestek, Axioma).๐ŸŽฏ Conducted security modeling for derivatives, including equity and FX options, FX forwards, futures, convertibles, TRS, IRS, MBS, and PERCs.๐ŸŽฏ Executed fair value modeling and shareholder flow forecasts across OppenheimerFunds' portfolios.๐ŸŽฏ Developed a mathematical model for predicting Morningstar ratings, utilized as a key insight by OppenheimerFunds' marketing department.๐ŸŽฏ Demonstrated proficiency in Python, Matlab, SQL, and Visual Basic (VBA).๐ŸŽฏ Gained experience in employing Bloomberg, FactSet, CRSP, Lipper, Morningstar, Ibbotson (Encorr) platforms, BarraOne, Northfield, ThomsonOne, and Global Financial Data (GFD).
  • Federal Reserve Bank Of Dallas
    Economic Research Associate
    Federal Reserve Bank Of Dallas 1997 - 1999
    I had the privilege of working alongside the Chief Economist and President of the bank on numerous research projects. These included the studies of inflation indices, living standards, energy pricing, and the role of technological innovation in driving the economy. As a team member and statistician, I am proud to have contributed to the Pulitzer Prize-nominated book, "Myths of Rich & Poor: Why Weโ€™re Better Off Than We Think," authored by W. Michael Cox and Richard Alm.

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ Skills

Asset Allocation Equities Quantitative Analytics Portfolio Management Hedge Funds Investments Portfolio Optimization Bloomberg Alternative Investments Financial Modeling Options Equity Research Fixed Income Derivatives Asset Management Econometrics Chartered Financial Analyst Investment Strategies Investment Management Capital Markets Securities Economics Valuation Financial Markets Quantitative Finance Quantitative Investing Etfs Risk Management Trading Systems Trading Strategies Mutual Funds Asset Managment Emerging Markets Equity Derivatives Trading Structured Products Investment Banking Market Risk Equity Valuation Bloomberg Terminal Structured Finance Cfa Python Machine Learning Data Science Portfolio Managers Matlab Smart Beta Risk Premia

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ Education Details

Frequently Asked Questions about Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ

What company does Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ work for?

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ works for Springer Nature Group

What is Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ's role at the current company?

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ's current role is Peer Reviewer in AI applied to Genetics.

What is Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ's email address?

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ's email address is sp****@****nds.com

What is Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ's direct phone number?

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ's direct phone number is (781)-522*****

What schools did Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ attend?

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ attended University Of Rochester - Simon Business School, University Of Houston, Southern Methodist University, Belarusian State University.

What skills is Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ known for?

Sergei Polevikov, Abd, Mba, Ms, Ma ๐Ÿ‡ฎ๐Ÿ‡ฑ๐Ÿ‡บ๐Ÿ‡ฆ has skills like Asset Allocation, Equities, Quantitative Analytics, Portfolio Management, Hedge Funds, Investments, Portfolio Optimization, Bloomberg, Alternative Investments, Financial Modeling, Options, Equity Research.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.